Precision Medicine in Oncology® | Specialty

Intraperitoneal Chemotherapy Improves Survival in Ovarian Cancer Patients With Low BRCA1 Levels

April 19th 2013

Patients with epithelial ovarian cancer (EOC) and low levels of the BRCA1 protein had significantly improved overall survival (OS) when their platinum-based chemotherapy was delivered abdominally by injection

April 2013 Biotech Focus: Tracking the Oncology Pipeline

April 19th 2013

The Biotech Focus series provides updates on advances in the oncology treatment pipeline. In each entry, summaries of ongoing research, breaking news, and FDA decisions relating to a variety of cancers are presented.

US Supreme Court Hears Arguments in BRCA1/2 Patenting Case

April 18th 2013

The question of whether it should be legal to patent genes has reached the US Supreme Court, and the impending decision by the highest federal court in the country could significantly transform the current research landscape.

Use of Personalized Medicine to Select Adjuvant Breast Cancer Therapy

April 17th 2013

Clinical trials are under way that may change the way risk of recurrence is assessed for early-stage breast cancer patients, allowing for individualization of therapy.

Emanuel Petricoin Describes Screening With Biomarkers

April 16th 2013

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses disease screening with biomarkers.

Embracing a Challenge: Breast Cancer Expert Pushes Forward After Much Success

April 12th 2013

An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.

Robust Oncology Pipeline Described

April 11th 2013

Oncology continues to lead all therapeutic areas in drug development research, with nearly 5500 of more than 17,000 projects in the works.

Palbociclib Receives Breakthrough Designation for Treatment of Breast Cancer

April 10th 2013

The drug palbociclib (formerly known as PD-0332991) has received has received a "breakthrough therapy designation" from the FDA for the treatment of patients with breast cancer.

Baselga Recaps Research Into Three Breast Cancer Pathways

April 9th 2013

José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

AACR Rally Protests Cuts to NIH Budget

April 8th 2013

Sign-toting scientists, students, patients, and caregivers gathered near the Carnegie Library in Washington, DC, to protest recent cuts to the budget of the National Institutes of Health, the largest funder of medical research in the world.

OncLive Collaborates With Renowned Cancer Centers

April 2nd 2013

Dana-Farber Cancer Institute and Seattle Cancer Care Alliance Join OncLive's Strategic Alliance Partnership Program.

(Molecular) Pathways, Pathways, and More Pathways

April 2nd 2013

The oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

Dr. Andre on Research in Metastatic Breast Cancer

April 2nd 2013

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche Médicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, discusses upcoming research in metastatic breast cancer.

Dr. Jennifer Brown on Mutations and Targets in CLL

April 1st 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses targeted therapies and mutations in chronic lymphocytic leukemia.

Imatinib Therapy Matures: GIST Research Sheds Light on Mutations, Drug Levels

March 26th 2013

Recently reported data demonstrate that the presence of a specific mutation in PDGFRA predicts for the lack of activity for the imatinib in patients with gastrointestinal stromal tumors.

BCR Inhibitors Show Promise in Treating Chronic Lymphocytic Leukemia

March 25th 2013

Two novel, oral drugs that target the B-Cell receptor signal transduction pathway could significantly change the way chronic lymphocytic leukemia is treated.

Emanuel Petricoin on Genomic Profiling and Targeted Therapy

March 22nd 2013

Emanuel "Chip" Petricoin III, PhD, from George Mason University, discusses the inability of DNA and RNA profiling to predict response to treatment with targeted therapies.

Dr. Cheson on Novel ADCs in Non-Hodgkin Lymphoma

March 20th 2013

Bruce D. Cheson, MD, from Georgetown Lombardi Comprehensive Cancer Center, discusses the prospect of using antibody drug conjugates in non-Hodgkin lymphomas, including follicular lymphoma.

Managing NETs in the Community Setting

March 14th 2013

Treating Neuroendocrine Tumors With Chemotherapy

March 14th 2013